Introduction {#s1}
============

Neonatal hypoxic ischemic encephalopathy (HIE) is one of the most common causes of severe neurological deficit in children, affecting an estimated 15 per 10,000 live births ([@B15]; American College of Obstetricians and Gynecologists, and American Academy of Pediatrics, 2014). Several reviews have suggested that therapeutic hypothermia (both whole body and selective head) reduces mortality and improves survival with normal neurological outcome and is now a standard treatment protocol for most neonatal centers in developed countries ([@B11]; [@B19]; [@B27]). Despite this, their effectiveness is still limited, with mortality rates of approximately 10% −20% in several large trials ([@B19]). As a result, alternative strategies, including the use of adjuvant therapies such as xenon, allopurinol, erythropoietin, magnesium sulfate, and melatonin, have been suggested ([@B30]). Other strategies suggested include cooling for longer periods of time, cooling at lower temperature or both ([@B36]).

Recently, several randomized controlled trials have examined the effects of such adjuvant therapy in neonates with HIE, yielding a complex evidence base that requires careful examination across different strategies ([@B7]; [@B1]; [@B3]; [@B12]). However, most of these studies are relatively small and the results remains inconclusive and mixed. There are no reviews that attempted to summarize these data from large studies.

Furthermore, previous meta-analyses have often compared the efficacy of treatment within pairs of active treatment, which provides limited insights into the overall treatment hierarchy as treatment effects are estimated from two different treatment comparison only ([@B19]; [@B29]). Over the past few years, the use of network meta-analyses which allows for the simultaneous comparison of two or more interventions has increasingly been used ([@B23]; [@B24]; [@B8]; [@B40]). Network meta-analysis includes both direct and indirect comparison within a single analysis, thereby providing an integrated and more holistic conclusion, providing decision makers with a more complete evidence matrix ([@B42]). In this study, we aimed to estimate the efficacy and safety of available neuroprotective interventions for HIE who participated in randomized controlled studies.

Materials and Methods {#s2}
=====================

Search Strategy {#s2_1}
---------------

A literature search was performed to identify for studies from inception to June 30, 2018, on the following databases: PubMed, EMBASE, CINAHL Plus, Allied and Complementary Medicines (AMED), and the Cochrane Central Register of Controlled Trials without any language restriction. We also obtained additional records by reviewing the reference list of the retrieved articles and other resources including Google Scholar, NDLTD database, and ClinicalTrials.gov. A full list of search terms can be found in [**eText**](#SM1){ref-type="supplementary-material"} in [**Supplementary Material**](#SM1){ref-type="supplementary-material"}.

Study Selection {#s2_2}
---------------

Studies were considered eligible for inclusion if they (1) were randomized controlled studies (RCT), (2) recruited term or preterm infants (gestational age ≥35 weeks) diagnosed with HIE (3) had a control group or comparison group, (4) sufficiently powered to detect differences in the outcome of death and/or disability, and (5) the infants were given any of the following as intervention: magnesium sulfate, deferoxamine, cannabinoids, melatonin, statin, topiramate, xenon, allopurinol, erythropoietin, N-acetylcysteine, or therapeutic hypothermia; either as single intervention or adjunct therapy. Studies which had significant methodological limitations such as poor description of inclusion/exclusion criteria were excluded.

Data Collection and Extraction {#s2_3}
------------------------------

All identified records were screened independently by titles and abstracts by two reviewers (CL and PC) and validated by another reviewer (SL). The full texts of relevant articles were retrieved for further eligibility assessment, extracted, and any discrepancies were resolved through discussion. The information extracted included the author, study design and population, outcomes, and quality of the study using a standardized data extraction form. We subsequently assessed the study quality using the Cochrane risk of bias assessment tool ([@B17]).

Outcome Measures {#s2_4}
----------------

The co-primary outcomes of interest were the composite of mortality or major neurodevelopmental disability and/or mortality assessed at least 18 months of age. Secondary outcomes include cerebral palsy, development delay based upon the mental development and psychomotor indices of the Bayley II scales of infant development ([@B5]), seizures, quality of vision and hearing, and potential adverse effects caused by the treatment.

Statistical Analyses {#s2_5}
--------------------

We used a stepwise approach whereby traditional meta-analysis was performed using the Mantel-Haenszel random-effects model since we expect the presence of heterogeneity. We calculated the risk ratio and risk difference for dichotomous outcomes, and its 95% confidence interval. To determine whether the benefit of treatment on outcomes was affected by the severity of encephalopathy, we examined subgroups for which the severity of encephalopathy was graded as moderate or severe on the basis of clinical examination and/or amplitude integrated electroencephalography. The consistency of the treatment effect across subgroups was explored by calculating the ratio of relative risks with 95% confidence interval. Potential small study publication bias was assessed using visual inspection of the funnel plot and Eggers test. Between studies heterogeneity was assessed using *I* ^2^ and Cochran's Q method.

We subsequently performed a network meta-analysis which combines the direct and indirect effects of treatment, allowing for simultaneous comparison of multiple treatments. These were ranked using the surface under the curve ranking (SUCRA). Inconsistency checks were performed for closed loop in the network ([@B18]; [@B41]). Subsequently, we calculated the number needed to treat (NNT) or number needed to harm (NNH) to better understand the potential benefits of different treatments examined. We used the odds ratios (OR) derived from the usual care comparison in network meta-analysis for mortality outcome to estimate the absolute benefits ([@B10]).

Preplanned sensitivity analyses include comparison between high versus low-middle income countries as well as severity of encephalopathy. All analyses were conducted using Stata version 13.0 (StataCorp, College TX). This study is registered with PROSPERO, number CRD42016053390.

Results {#s3}
=======

Study Selection and Characteristics {#s3_1}
-----------------------------------

The literature search identified a total of 1,731 studies and 71 full-text articles were assessed for eligibility ([**Figure 1**](#f1){ref-type="fig"} and [**eTables 1**](#SM1){ref-type="supplementary-material"} and [**2**](#SM1){ref-type="supplementary-material"}). Fifteen studies enrolling 2,313 newborns were included in the review ([@B14]; [@B34]; [@B25]; [@B44]; [@B37]; [@B43]; [@B21]; [@B3]; [@B33]; [@B26]; [@B38]). Most of the included studies had a similar enrollment criteria and included infants with evidence of birth asphyxia as defined by the American College of Obstetrician and Gynecologists (American College of Obstetricians and Gynecologists, and American Academy of Pediatrics, 2014) with moderate to severe HIE. These studies had recruited newborns which were at least 35 weeks in 1 study, at least 36 weeks in 3 studies, and gestation weeks of more than or equal to 37 weeks in 9 studies. Interventions examined by studies were therapeutic hypothermia examined in 10 studies (8 whole body cooling and 2 selective head cooling), magnesium sulfate in 2 studies, erythropoietin in 2 studies, and use of xenon with therapeutic hypothermia in 1 study ([**Table 1**](#T1){ref-type="table"}). Eight studies (53.3%) were published in 2011 or later, and the studies were conducted in India (40%), China (20%), or were multicentered studies (20%). Nine studies (60%) had a duration (from recruitment to end of follow-up) of at least 18 months or more.

![Study flow detailing the screening, identification, and selection process.](fphar-10-01221-g001){#f1}

###### 

Characteristics of included studies.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                                                                                                      First Author,\                                                                                                                                         Study Population                                                                                                                                                                                                                                 Interventions                                                                                                                           Number of Patients Enrolled   Mean gestational age or age range, weeks
                                                                                                                                                                                                      Year (Study)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  ------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------- ----------------------------- ------------------------------------------
  **Drug Intervention as Single Treatment**   **Erythropoietin**                                                                                                                                      [@B26]                                                                                                                                                 Neonates (≥37 weeks) with moderate or severe HIE (10 min Apgar score \<5) evidence of fetal distress, need for resuscitation at 10 mins after birth                                                                                              **I:** 500 U/kg rhEPO intravenously on alternate dose for a total of 5 doses with the 1^st^ dose within 6 hours after birth\            100                           39.5
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              **C:** 2mL of normal saline                                                                                                                                           

  [@B44]                                      Term neonates (≥37 weeks), body weights \>2500 g with evidence of perinatal HIE (5-min Apgar score ≤5, need for resuscitation at 10 mins after birth)   **I:** 300 U/kg or 500 U/kg rhEPO subcutaneously for 1^st^ dose and intravenously every other day for 2 weeks\                                         167                                                                                                                                                                                                                                              37.5                                                                                                                                                                  
                                                                                                                                                                                                      **C:** Conventional treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  **Magnesium**                               [@B33]                                                                                                                                                  Term neonates with perinatal asphyxia, 1-min Apgar score \< 7, need for resuscitation at birth, failure to initiate breath at birth                    **I:** 250 mg/kg MgSO~4~ intravenous infusion over 1 h within 6 h of birth, with additional doses repeated at 24 h and 48 h\                                                                                                                     120                                                                                                                                     38.5                          
                                                                                                                                                                                                                                                                                                                                                             **C:** Supportive care                                                                                                                                                                                                                                                                                                                                                                                                 

  [@B38]                                      Term neonates with perinatal asphyxia, 1-min Apgar score \<3 or 5-min Apgar score \<6                                                                   **I:** 250 mg/kg MgSO~4~ intravenous infusion over 1 h within 6 h of birth, with additional doses repeated at 24 h and 48 h\                           100                                                                                                                                                                                                                                              38.7                                                                                                                                                                  
                                                                                                                                                                                                      **C:** Supportive care                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  **Cooling (Whole body)**                    [@B4] (TOBY)                                                                                                                                            Term neonates (≥36 gestation weeks) with moderate to severe HIE, Apgar score \<6, seizure on aEEG                                                      **I:** Manually adjusted cooling blanket to target rectal temperature of 33.0°C--34.0°C for 72hr\                                                                                                                                                325                                                                                                                                     38.8--41.3^†^                 
                                                                                                                                                                                                                                                                                                                                                             **C:** Conventional care with overhead radiant heater to target rectal temperature of 36.8°C--37.2°C                                                                                                                                                                                                                                                                                                                   

  [@B6]                                       Term neonates (\>37 gestation weeks) with perinatal asphyxia (10-min Apgar score ≤6), and encephalopathy                                                **I:** Whole body cooling with gel packs to target rectal temperature of 33.0 °C--34.0°C\                                                              130                                                                                                                                                                                                                                              40.0                                                                                                                                                                  
                                                                                                                                                                                                      **C:** Conventional care with servo-controlled overhead radiant heater to target rectal temperature of 36.5°C                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  **Drug Intervention as Single Treatment**   **Cooling (Whole body)**                                                                                                                                [@B13]                                                                                                                                                 Term neonates (≥37 weeks) with evidence of encephalopathy (10-min Apgar \<5)                                                                                                                                                                     **I:** Cloth covered gel packs to target rectal temperature of 33°C--34°C for 72 h\                                                     122                           40.1
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              **C:** Conventional care for HIE to target of 36.5°C                                                                                                                  

                                                                                                                                                                                                      [@B20] (ICE)                                                                                                                                           Term or near term neonates (≥35 gestation weeks) with moderate to severe HIE, perinatal asphyxia, 10-min Apgar score \<6                                                                                                                         **I:** Refrigerated gel pack across chest and/or under head and shoulders to target rectal temperature of 33.0°C--34.0°C for 6--72 h\   221                           39.1
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              **C:** Conventional care with overhead radiant heater to target rectal temperature of 36.8°C --37.2°C                                                                 

                                                                                                                                                                                                      [@B21]                                                                                                                                                 Term neonates (≥37 weeks) with evidence of encephalopathy (10-min Apgar ≤5)                                                                                                                                                                      **I:** Cloth covered gel packs to target rectal temperature of 33--34 °C for 72 h\                                                      160                           \-
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              **C:** Conventional care for HIE to target rectal temperature of 36.5°C                                                                                               

                                                                                                                                                                                                      [@B25]                                                                                                                                                 Term neonates (≥37 weeks), weight \> 2500 g, with moderate to severe encephalopathy (5-min Apgar ≤5)                                                                                                                                             **I:** Whole body cooling with cooling mattress to target rectal temperature of 33 °C--34 °C for 72 h\                                  93                            39.1
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              **C:** Conventional care for HIE to target rectal temperature of 36.5°C--37.5 °C                                                                                      

                                                                                                                                                                                                      [@B34]\                                                                                                                                                Term neonates (≥37 gestation weeks) with moderate to severe HIE, perinatal asphyxia (10 min Apgar score ≤5))                                                                                                                                     **I:** Two servo-controlled cooling blanket to target oesophageal temperature of 34.5 °C for 72 h\                                      208                           4.3 h\*
                                                                                                                                                                                                      (NICHD study)                                                                                                                                                                                                                                                                                                                                                                                           **C:** Conventional care with overhead radiant heater to target skin temperature of 36.5 °C--37.0 °C                                                                  

                                                                                                                                                                                                      [@B37]\                                                                                                                                                Term neonates (≥36 gestation weeks) with moderate to severe HIE, perinatal asphyxia (10 min Apgar score \<5) and encephalopathy as evidence by abnormal standard EEG or aEEG findings                                                            **I:** Cooling blanket to target rectal temperature of 33.0°C--34.0°C for 72 h\                                                         129                           39.3
                                                                                                                                                                                                      (neo,nEURO)                                                                                                                                                                                                                                                                                                                                                                                             **C:** Conventional care to target rectal temperature of 36.5°C--37.5°C                                                                                               

                                              **Cooling (Selective head)**                                                                                                                            [@B14]\                                                                                                                                                Term neonates (≥37 gestation weeks) with moderate to severe HIE, perinatal asphyxia, 10-min Apgar score ≤5, severe acidosis (pH \< 7) or a base deficit of 16 mmol/L                                                                             **I:** Manual controlled cooling cap to target temperature of 34.0°C --35.0°C for 72 h\                                                 234                           39.0
                                                                                                                                                                                                      (CoolCap)                                                                                                                                                                                                                                                                                                                                                                                               **C:** Conventional care with overhead radiant heater to target of 36.5°C --37.5°C                                                                                    

                                              [@B43]                                                                                                                                                  Term neonates (≥37 gestation weeks) with perinatal asphyxia (5-min Apgar score ≤5 or 1-min Apgar score ≤3), birth weight ≥2500 g, and encephalopathy   **I:** Manually controlled cooling cap to rectal target temperature of 34.5°C --35.0°C for 72 h\                                                                                                                                                 194                                                                                                                                     4.0 h\*                       
                                                                                                                                                                                                                                                                                                                                                             **C:** Conventional care whereby infants are cared on radiant warmers servo-controlled to rectal target of 36.0°C--37.5°C                                                                                                                                                                                                                                                                                              

  **Drug Intervention as Adjuvant**           **Xenon**                                                                                                                                               [@B3] (TOBY-Xe)                                                                                                                                        Gestation weeks (36--43 weeks), had signs of moderate to severe encephalopathy, moderately or severely abnormal background activity for ≥30 min or seizures shown by aEEG, 10-min Apgar score ≤5, continued need for resuscitation for ≥10 min   **I:** Whole body hypothermia to target rectal temperature of 33.5°C plus 30% inhaled xenon for 24 h\                                   92                            39.8
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              **C:** Whole body hypothermia alone to target rectal temperature of 33.5°C                                                                                            
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AAP, American Association of Pediatrics; ACOG, American College of Obstetricians and Gynecologists; aEEG, amplitude-integrated continuous electroencephalopathy; C, control group; CBV, cerebral blood volume; EAA, excitatory amino acids; EPO, erythropoietin; 1^st^, first; I, intervention group; h, hours; HIE, hypoxic-ischemic encephalopathy; MgSO~4~, magnesium sulfate; min, minutes; m, months; NaCl, normal saline; NO, nitric oxide; rhEPO, recombinant human erythropoietin; subcut, subcutaneously.

\* Age at randomization; ^†^Interquartile range.

Methodological Quality of Included Studies {#s3_2}
------------------------------------------

Twelve (80.0%) studies had adequate reporting on sequence generation, 12 (80.0%) studies described the loss to follow-up, 10 (66.7%) studies described the selection concealment adequately, and 6 (40.0%) studies described the blinding of participants and outcome assessment. However, a high proportion \[10 (66.7%)\] had unclear risk of bias for blinding of outcome assessors ([**eFigure 1**](#SM1){ref-type="supplementary-material"}).

Primary Outcomes {#s3_3}
----------------

### Mortality {#s3_3_1}

Fifteen RCTs reported the effectiveness of intervention in reducing the risk of mortality. Pairwise meta-analysis showed that whole body hypothermia was effective in reducing the risk of mortality (OR: 0.71; 0.52--0.92, *I* ^2^ = 0%) compared to usual care ([**eTable 3**](#SM1){ref-type="supplementary-material"}).

### Mortality and/or Neurodevelopmental Delay at 18 Months {#s3_3_2}

Nine studies reported the long term effects of pharmacotherapy or hypothermia on mortality and neurodevelopmental delay at 18 months ([@B14]; [@B34]; [@B4]; [@B25]; [@B44]; [@B37]; [@B43]; [@B20]; [@B26]). Pooled analysis of studies suggest that both erythropoietin (OR: 0.57; 0.36--0.91, *I* ^2^ = 0%) and whole body hypothermia (0.74; 0.59--0.92, *I* ^2^ = 0%) were effective in reducing the risk of mortality and neurodevelopmental delay at 18 months.

### Secondary Outcomes {#s3_3_3}

Among infants who survived, 12 trials including 1,951 infants reported on cerebral palsy outcome. Whole body hypothermia was found to be statistically superior in reducing the odds developing cerebral palsy (0.70; 0.54--0.92, *I* ^2^ = 0%) compared to usual care. With respect to seizures, 10 trials including 1,703 infants were included. Whole body hypothermia was superior in reducing the rates of seizure compared to usual care (0.73; 0.56--0.96, *I* ^2^ = 0%).

Five studies reported the neuromotor delay and neurodevelopmental delay among neonates using the Bayley II index, but results were not significant. For the other outcomes of renal failure, sepsis, hypotension, hypoglycemia, bradycardia, hearing loss, and blindness, the evidence base were sparse ([**eTable 4**](#SM1){ref-type="supplementary-material"}). Meta-analysis suggests that therapeutic hypothermia (both whole body and selective head cooling) were associated with an increased rate of normal survival, defined as survival without cerebral palsy, seizures, normal vision, and hearing.

Effect of Severity of Encephalopathy {#s3_4}
------------------------------------

Most studies assessed the severity of encephalopathy by clinical assessment using Sarnat's criteria ([@B32]), which classifies the degree of encephalopathy to either stages I, II or III, correlating with mild, moderate or severe encephalopathy. Pooled analysis suggests that the relative odds of mortality or neurodevelopmental disability were lower among infants with moderate encephalopathy when treated with erythropoietin (0.27; 0.11--0.63, *I* ^2^ = 0%) or whole body hypothermia (0.63; 0.44--0.89, *I* ^2^ = 0%). Among infants with severe encephalopathy, all interventions including erythropoietin, whole body hypothermia or selective head hypothermia was ineffective in reducing the risk of combined outcomes of mortality or neurodevelopmental disability ([**eTable 5**](#SM1){ref-type="supplementary-material"}).

Network Meta-Analysis {#s3_5}
---------------------

### Mortality or Mortality and Neurodevelopmental Disability at 18 Months {#s3_5_1}

Overall, of the 15 unique pairwise comparisons that could be made, only 5 were studied head to head. The network meta-analysis gave an adequate fit to the data and design-by-treatment model showed no evidence of inconsistency ([**eFigure 2**](#SM1){ref-type="supplementary-material"}).

All interventions examined showed a reduction in risk of mortality compared to usual care ([**Figure 2**](#f2){ref-type="fig"}, [**Table 2**](#T2){ref-type="table"} and [**eTable 6**](#SM1){ref-type="supplementary-material"}). However, only whole body hypothermia was significantly better than usual care (0.62; 0.46--0.83), with an NNT of 11 (95% CI: 7--26) in reducing the risk of mortality ([**eTable 7**](#SM1){ref-type="supplementary-material"}). With respect to the composite mortality or neurodevelopmental disability outcome at 18 months or longer, erythropoietin was significantly better than usual care in patients with moderate encephalopathy (0.36; 0.19--0.66; [**eFigure 3**](#SM1){ref-type="supplementary-material"}). Therapeutic hypothermia (both whole body and selective head cooling) was the only treatment statistically superior to usual care in patients with moderate (whole body: 0.45; 0.31--0.66 and selective head: 0.51; 0.29--0.89) or severe encephalopathy (whole body: 0.32; 0.12--0.86).

![Network meta-analysis forest plots for each treatment versus usual care on mortality or mortality and neurodevelopmental delay at 18 months outcome. Each rhombus represents the summary treatment effect estimated in the network meta-analysis on the odds ratio (OR) scale. The black horizontal lines represent the credible intervals (CrI) for the summary treatment effects; an OR \> 1 suggests that usual care is more effective to reduce the risk of mortality, whereas an OR \< 1 suggests that the comparable treatment is better. The vertical blue line corresponds to an OR = 1.](fphar-10-01221-g002){#f2}

###### 

Network meta-analysis for primary outcomes mortality.

  ---------------------------- -------------------------------- -------------------- ----------------------- ----------------------- --------------------------
  **Whole body hypothermia**   1.11 (0.59, 2.08)                0.66 (0.26, 1.67)    0.78 (0.20, 3.14)       0.77 (0.29, 2.09)       [0.62 (0.46, 0.83)]{.ul}

                               **Selective head hypothermia**   0.78 (0.30, 2.07)    0.92 (0.22, 3.83)       0.91 (0.30, 2.79)       0.73 (0.48, 1.11)

                                                                **Erythropoietin**   1.18 (0.24, 5.96)       1.17 (0.30, 4.55)       0.93 (0.39, 2.25)

                                                                                     **Magnesium sulfate**   0.99 (0.18, 5.45)       0.79 (0.20, 3.06)

                                                                                                             **Whole body**\         0.80 (0.28, 2.26)
                                                                                                             **hypothermia with**\   
                                                                                                             **xenon**               

                                                                                                                                     **Usual care**
  ---------------------------- -------------------------------- -------------------- ----------------------- ----------------------- --------------------------

Comparisons should be read from left to right. The estimate is located at the intersection of the column-defining treatment and the row-defining treatment. An OR value below 1 favors the column-defining treatment. To obtain ORs for comparisons in the opposing direction, reciprocals should be taken. Any significant results are in bold and underlined.

### Secondary Outcomes {#s3_5_2}

Network meta-analysis suggest that, compared to usual care, treatment with either erythropoietin or whole body hypothermia were associated with lower rates of cerebral palsy (0.36; 0.18--0.74 and 0.61; 0.45--0.83, respectively) and seizures (0.35; 0.13-- 0.94 and 0.64; 0.46--0.87, [**Figure 3**](#f3){ref-type="fig"}).

![Network meta-analysis forest plots for each treatment versus usual care on secondary outcomes. Each rhombus represents the summary treatment effect estimated in the network meta-analysis on the odds ratio (OR) scale. The black horizontal lines represent the credible intervals (CrI) for the summary treatment effects; an odds ratio \> 1 suggests that usual care is more effective to reduce the risk of mortality, whereas an OR \< 1 suggests that the comparable treatment is better. The vertical blue line corresponds to an OR = 1.](fphar-10-01221-g003){#f3}

### Sensitivity Analyses {#s3_5_3}

Comparison-adjusted funnel plots of the network meta-analysis for primary outcomes did not suggest any publication bias ([**eFigure 4**](#SM1){ref-type="supplementary-material"}). Ranking of treatment based upon cumulative probability plots ([**eFigure 5**](#SM1){ref-type="supplementary-material"}) and SUCRA showed that the most effective treatment for primary outcome mortality was whole body hypothermia (77.8%) and the least effective was usual care (24.5%). In terms of the composite outcome of mortality or neurodevelopmental disability at 18 months, the most effective treatment was erythropoietin (88.8%) and the least effective was usual care (0.2%). Using GRADE, the quality of evidence for primary outcomes were moderate to very low for most comparison ([**Table 3**](#T3){ref-type="table"} and [**eTable 8**](#SM1){ref-type="supplementary-material"}).

###### 

Summary of findings table for the primary outcomes assessed in this study.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Estimates of effects, credible intervals, and certainty of the evidence for comparison of neuroprotective therapies for neonates with hypoxic ischemic encaphalopathy                                                                                                                                                                                                                 
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------- --------------------------------------- --------------------------- ---------------------------- ------------------------------- ------------------------------ ---------------------------------------------------------------------------------------------------------
  Patient or population: Neonates with hypoxic ischemic encephalopathy\                                                                                                   ![](fphar-10-01221-g004.jpg)\                                                                                                                                                                                 
  Interventions: Whole body cooling, selective head cooling, magnesium sulfate, erythropoietin, whole body cooling with xenon\                                            Geometry of the Network                                                                                                                                                                                       
  Comparator (reference): Usual care\                                                                                                                                                                                                                                                                                                                                                   
  Outcome: Mortality; mortality or neurodevelopmental disability at 18 months or later\                                                                                                                                                                                                                                                                                                 
  Setting(s): Inpatient and outpatient                                                                                                                                                                                                                                                                                                                                                  

  Total studies:15 RCT\                                                                                                                                                   Odds ratio\                                   Anticipated absolute effect (95% CrI)   Certainty of the evidence   Interpretation of Findings                                                                  
  Total Participants: 2,103                                                                                                                                               (95% CrI)\                                                                                                                                                                                                    

  With placebo                                                                                                                                                            With intervention                             Difference                                                                                                                                                      

  Mortality                                                                                                                                                                                                                                                                                                                                                                             

  •                                                                                                                                                                       Whole body cooling\                           **0.62**\                               261 per 1,000               180 per 1,000                81 fewer per 1,000\             ![](fphar-10-01221-g005.jpg)   Whole body cooling improves survival in newborns with HIE
                                                                                                                                                                          (Direct evidence; 8 RCT; 1324 participants)   (0.46 to 0.83)                                                                                   (from 121 fewer to 34 fewer)                                   

  •                                                                                                                                                                       Selective head cooling\                       **0.73**\                               259 per 1,000               204 per 1,000                56 fewer per 1,000\             ![](fphar-10-01221-g006.jpg)   Selective head cooling probably improves survival in newborns with HIE
                                                                                                                                                                          (Direct evidence; 2 RCT; 428 participants)    (0.48 to 1.11)                                                                                   (from 115 fewer to 21 more)                                    

  •                                                                                                                                                                       Magnesium sulfate\                            **0.79**\                               36 per 1,000                29 per 1,000                 7 fewer per 1,000\              ![](fphar-10-01221-g007.jpg)   Use of magnesium sulfate has limited effect on survival in newborns with HIE
                                                                                                                                                                          (Direct evidence; 2 RCT; 220 participants)    (0.20 to 3.06)                                                                                   (from 29 fewer to 67 more)                                     

  •                                                                                                                                                                       Erythropoietin\                               **0.93**\                               89 per 1,000                84 per 1,000                 6 fewer per 1,000\              ![](fphar-10-01221-g008.jpg)   Use of erythropoietin has limited effect on survival in newborns with HIE
                                                                                                                                                                          (Direct evidence; 2 RCT; 253 participants)    (0.39 to 2.25)                                                                                   (from 53 fewer to 92 more)                                     

  •                                                                                                                                                                       Whole body cooling with xenon\                **0.80**\                               196 per 1,000               163 per 1,000                33 fewer per 1,000\             ![](fphar-10-01221-g009.jpg)   Use of xenon as an adjuvant with whole body cooling has limited effect on survival in newborns with HIE
                                                                                                                                                                          (Indirect evidence; 1 RCT; 92 participants)   (0.28 to 2.26)                                                                                   (from 132 fewer to 159 more)                                   

  Mortality or neurodevelopmental delay at 18 months                                                                                                                                                                                                                                                                                                                                    

  •                                                                                                                                                                       Whole body cooling\                           0.54\                                   607 per 1,000               455 per 1,000                152 fewer per 1,000\            ![](fphar-10-01221-g010.jpg)   Whole body cooling improves survival and neurodevelopment in newborns with HIE
                                                                                                                                                                          (Direct evidence; 5 RCT; 934 participants)    (0.32 to 0.89)                                                                                   (from 276 fewer to 28 fewer)                                   

  •                                                                                                                                                                       Selective head cooling\                       **0.49**\                               583 per 1,000               407 per 1,000                176 fewer per 1,000\            ![](fphar-10-01221-g011.jpg)   Selective head cooling probably improves survival and neurodevelopment in newborns with HIE
                                                                                                                                                                          (Direct evidence; 2 RCT; 412 participants)    (0.33 to 0.72)                                                                                   (from 267 fewer to 81 fewer)                                   

  •                                                                                                                                                                       Erythropoietin\                               **0.36**\                               538 per 1,000               296 per 1,000                243 fewer per 1,000\            ![](fphar-10-01221-g012.jpg)   Use of erythropoietin probably improves survival and neurodevelopment in newborns with HIE
                                                                                                                                                                          (Direct evidence; 2 RCT; 253 participants)    (0.29 to 0.67)                                                                                   (from 286 fewer to 100 fewer)                                  
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^1^Study was downgraded due to imprecision and lack of direct RCTs contributing to direct evidence; ^2^Few event rates with wide confidence intervals leading to imprecision; ^3^Serious indirectness; ^4^Contributing direct evidence of moderate quality with inadequate concealment of allocation and blinding.

In the preplanned sensitivity analyses, we excluded studies which were conducted in low-middle income countries since previous meta-analysis have suggested that these study setting could influence the results ([@B29]). When studies from high-income countries were only included, only three comparisons were possible for the outcome of mortality. Results from the network meta-analysis was largely unchanged, and whole body cooling was found to reduce the risk of mortality by 36% (0.64; 0.46--0.90) as well as mortality or major neurodevelopmental disability at 18 months by 49% (0.51; 0.33--0.78) compared to usual care. These results were largely unchanged when we included studies which had examined full term neonates (≥37 weeks), where whole body cooling reduced the risk of mortality (0.50; 0.31--0.81) as well as mortality or major neurodevelopmental disability at 18 months (0.44; 0.27--0.71) compared to usual care ([**eTable 9**](#SM1){ref-type="supplementary-material"}). In addition, selective head cooling was also noted to lower the risk of mortality or major neurodevelopmental disability at 18 months compared to usual care (0.54; 0.36--0.81).

Discussion {#s4}
==========

In this study, direct and indirect evidence from 15 RCTs was combined to compare the association of each therapy used for neuroprotection in HIE. The study has several key findings. Firstly, therapeutic hypothermia was significantly associated with lower odds of mortality and neurodevelopmental delays compared to usual care, with high confidence estimates and a number to treat of between 11 and 16. Secondly, whole body hypothermia should be offered to all infants with HIE, irrespective of the severity as it was effective in reducing the risk of morbidity as well as neurodevelopmental delays when compared to usual care.

Over the past decade, numerous drugs have been proven useful to be beneficial in animal models for neonates with HIE, but how these can be translated into clinical use remains unknown ([@B28]). Our study provides novel insights into how different neuroprotective agents could be useful in patients with HIE especially when used in combination with hypothermia ([@B27]). Although there is much progress, further studies are needed to determine the effectiveness of these adjuvant therapies. Several large clinical studies are underway to examine the benefits of these neuroprotective agents.

A previous review suggested that key differences exists in terms of efficacy between high-income and low-middle income countries, due to the use of low-technology devices, degree of encephalopathy, maternal pre-existing diseases, malnutrition status, infections, as well as study inclusion criteria ([@B29]). In this study, we showed that therapeutic hypothermia especially whole body hypothermia was the most effective intervention irrespective of study setting as well as device used. As HIE is the major cause of up to 23% of 2.8 million neonatal deaths especially in low-resource setting, our findings provide a further impetus for therapeutic hypothermia to be part of standard of care especially in low-middle income countries.

Our findings support the Cochrane review on hypothermia in patients with HIE for the primary outcome, where we found that cooling was beneficial in reducing the risk of mortality and disability ([@B19]). This has similarly been reported by other authors which concluded that hypothermia improves survival and neurodevelopmental delays in newborns ([@B39]; [@B9]). The current review was larger (an additional 4 RCTs and 808 infants) and includes information on the effectiveness of different neuroprotective agents. While the authors of a recent systematic review on hypothermia did not conduct network meta-analysis, the results presented were similar to those reported here and suggest that therapeutic hypothermia is effective.

Study Strength {#s4_1}
--------------

Strengths of our review are that we conducted a comprehensive search as well as the identification of new additional studies. We also used multiple approaches to assess the relationship of effects and performed a network meta-analysis, which provides added information on effects of different combination of interventions (drugs and non-drugs). The quality of the evidence generated were rated using the GRADE criterion ([@B31]). We used a comprehensive search strategy and searched all pertinent sources for eligible studies, which reduces the possibility of missing any relevant studies. This study also included preterm infants ≥35 weeks as part of the inclusion criteria and provides a more holistic overview on the clinical safety and efficacy of therapeutic hypothermia in this group of infants where data on outcomes are sparse. Nevertheless, these results need to be confirmed from larger randomized controlled trials such as the Premmie Hypothermia for Neonatal Encephalopathy study which is currently in progress (NCT01793129). Until then, clinicians should take precaution especially when treating preterm neonates since evidence from a recent retrospective cohort analysis have suggested that a high incidence of complication and composite outcome of death and neurodevelopmental impairment ([@B16]).

Study Limitations {#s4_2}
-----------------

The limitations of our review are the inherent heterogeneity in terms of study design, intervention, as well as outcome assessment of included studies. We attempted to minimize this by using rigorous selection criteria and performing several sensitivity analyses to ensure the robustness of our results. Secondly, analysis for other outcomes such as neurodevelopmental outcomes, blindness, as well as adverse events should be interpreted with caution, owing to the few data points available. However, a recent high quality long-term study on effects of depth and duration of cooling showed that there is little to no effect of different hypothermia therapy or duration of therapy on outcome ([@B35]; [@B22]). This independent analysis reinforces the case that hypothermia should be standard therapy, and additional policy options may be needed in low resource settings to improve outcomes. As with most network meta-analyses, there were only sparse data for some of the treatment comparison especially those related to erythropoietin, and thus, it is recommended that these treatment effect estimates be interpreted together with their precision.

Our study also revealed that additional studies are needed to further optimize cooling therapy as well as rewarming methods, such as the recently concluded NICHD funded study which examined the impact of different cooling depth and duration in neonates with HIE ([@B35]; [@B22]). In addition, sufficiently powered studies which examine the use of adjuvant therapies in addition to hypothermia are needed. Another research goal is to reliably identify for subgroups of newborns who will go on to develop worsening encephalopathy and significant brain injury, possibly through the use of electroencephalography, or other biomarker to ensure that they benefit most from hypothermia. In summary, results of our analysis generally support current guidelines using hypothermia for neonates with HIE irrespective of setting. Our findings further support whole body hypothermia as first line, due to its ease of use, improving mortality and neurodevelopmental outcomes. However, further research is needed to determine if the use of additional adjuvant therapies could further improve outcomes of HIE.
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